Traditional implants in the gastrointestinal tract are meant to pass through a patient’s system, delivering a drug in short bursts or recording the health of a patient’s colon.
But in recent years, scientists have sought after ultra-long lasting ingestible devices that can deliver drugs for several weeks in a patient’s GI tract. Lyndra, Inc., a start-up based on such technology from the Massachusetts Institute of Technology, raised $23 million in April to support development of its star-shaped capsule.
Sustained-release drug delivery devices that reside in the gastrointestinal tract require a power source and, as gastroenterologist Giovanni Traverso told Drug Delivery Business News, batteries don’t make the cut.
Get the full story at our sister site, Drug Delivery Business News.